

IL13

Recombinant Human Interleukin-13 Variant

Catalog No.	CSI20282A CSI20282B CSI20282C	Quantity:	2 µg 10 µg 1.0 mg
Alternate Names:	Interleukin-13, ALRH, BHR1, IL-13		
Description:	<p>Recombinant Human Interleukin-13 Variant is a single, non-glycosylated polypeptide chain containing 112 amino acids, with a substitution of Q for R at position 112 compared with the wild type IL-13.</p> <p>Background: The human IL-13 cDNA encodes a 132 amino acid protein containing a proposed 20 amino acid signal peptide. Human IL-13 shares approximately 30% amino acid sequence homology to human IL-4 and the two cytokines exhibit overlapping biological activities. Human IL-13 is produced by activated Th0, Th1-like, Th2-like, and CD8 T cells. Similarly to IL-4, IL-13 has multiple effects on the differentiation and functions of monocytes/macrophages. IL-13 can suppress the cytotoxic functions of monocytes/macrophages. It can also suppress the production of proinflammatory cytokines and upregulate the production of IL-1ra by monocytes/macrophages.</p>		
Gene ID:	3596		
Source:	<i>E. coli</i>		
Molecular Weight:	~12.3 kDa		
Formulation:	Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.2, containing 5% trehalose.		
Purity:	>97% by SDS-PAGE and HPLC analyses.		
Endotoxin Level:	Less than 1 EU/µg of rHuIL-13 variant as determined by LAL method.		
Biological Activity:	Fully biologically active when compared to standard. The ED ₅₀ as determined a cell proliferation assay using human TF-1 cells is less than 0.5 ng/ml.		
Specific Activity:	>2.0 × 10 ⁶ IU/mg		
Amino Acid Sequence:	GPVPPSTALR ELIEELVNIT QNQKAPLCNG SMVWSINLTA GMYCAALES INVSGCSAIE KTQRMLSGFC PHKVSAGQFS SLHVRDTKIE VAQFVKDLLL HLKCLFREGQ FN		
Reconstitution:	Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions. Stock solutions should be apportioned into working aliquots and stored at <-20°C. Further dilutions should be made in appropriate buffered solutions.		
Storage & Stability:	This lyophilized preparation is stable at 2-4°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -80°C. Avoid repeated freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

